Oruka's $1.2B War Chest Fuels a Twice-Yearly Psoriasis Blockbuster Threat

MENLO PARK, Calif. – November 09, 2026 – The immunology market is a multi-billion dollar battlefield currently dominated by entrenched pharmaceutical giants. For years, AbbVie's Skyrizi and Janssen's Tremfya have set the commercial standard for plaque psoriasis treatments. But market momentum is a fickle force, and today, Oruka Therapeutics (Nasdaq: ORKA) signaled it is ready to upend the status quo.

Releasing its third-quarter 2026 financial results and a slate of clinical updates, the clinical-stage biotech revealed a potent combination of deepened clinical efficacy, unprecedented durability, and a massive $1.2 billion war chest. For investors and industry watchers tracking the "why behind the buy," the catalyst here is clear: Oruka is aggressively positioning its lead candidate to disrupt standard-of-care dosing regimens, backed by a balance sheet that makes immediate shareholder dilution a non-issue.

Dosing Disruption: Unseating the Psoriasis Blockbusters

To understand the threat Oruka poses to existing immunology franchises, one must look closely at the data. In October, the company announced positive Week 16 results from the EVERLAST-B Phase 2b trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody. The numbers are striking. In the 600 mg high-dose cohort, 61% of patients achieved PASI 100 (complete skin clearance), and 86% achieved PASI 90.

To contextualize this market threat, we must benchmark these figures against the reigning champions. Skyrizi achieved a 47% PASI 100 and 73% PASI 90 at Week 16 in its Phase 3 IMMhance trial. Tremfya’s VOYAGE trials reported PASI 90 rates hovering around 70% to 73% at the same time point. ORKA-001 is not just matching the standard of care; early data suggests it is materially exceeding it.

But the real catalyst for market disruption lies in the drug's durability. Oruka’s EVERLAST-A Phase 2a trial demonstrated that clinical responses continued to deepen over time. Astoundingly, PASI 100 rates increased to 71% at Week 28—a full six months after the last dose was administered. This sustained response is the holy grail of biologic therapy, powered by Oruka's proprietary half-life extension technology.

While Skyrizi requires maintenance dosing every 12 weeks and Tremfya every eight weeks, ORKA-001 is charting a course toward once- or twice-yearly administration. In a market where patient compliance and convenience dictate commercial success, reducing injections to a biannual schedule could trigger a massive shift in physician preference and effectively siphon market share from today's market leaders.

The $1.2 Billion Moat: De-Risking the Phase 3 Cliff

Clinical promise frequently dies on the vine of financial reality, particularly in the notoriously expensive Phase 3 development stage. This is where Oruka’s third-quarter earnings report fundamentally alters its risk profile. As of September 30, 2026, the company reported an eye-watering $1.2 billion in cash, cash equivalents, and marketable securities.

During the third quarter, net cash used in operating activities was $44.3 million. Research and development expenses climbed to $53.7 million, up from $29.0 million in the prior year, reflecting the accelerated pace of clinical trials and increased headcount. General and administrative expenses also rose to $8.4 million to support the growing operations. Overall net loss for the quarter stood at $50.0 million. Notably, the massive cash reserve generated $12.2 million in interest income for the quarter, significantly offsetting operational costs compared to the $3.8 million earned in the same period last year.

Applying that quarterly operating burn rate against their capital reserves reveals a financial runway approaching seven years. This is a staggering moat for a mid-cap biotech. It means Oruka can fully fund its upcoming Phase 3 trials for ORKA-001—slated to begin in the first half of 2027—without the looming threat of dilutive equity raises that typically suppress biotech valuations as they approach late-stage clinical hurdles.

“We continued to make rapid progress in the third quarter and shared two new datasets from the EVERLAST program with ORKA-001 that further strengthen our belief that it can set a new standard in psoriatic disease,” stated Lawrence Klein, PhD, Chief Executive Officer of Oruka. “We look forward to sharing 52-week data from EVERLAST-A later this year and then working to rapidly initiate pivotal studies with this very promising asset.”

Beyond Monotherapy: A Multi-Target Immunology Play

While ORKA-001 is the tip of the spear, Oruka is aggressively building out a multi-target immunology franchise to ensure long-term corporate performance. The company’s secondary asset, ORKA-002, is a novel half-life extended IL-17A/F monoclonal antibody. The ORCA-SURGE Phase 2 dose-ranging trial in moderate-to-severe psoriasis has already completed enrollment of 171 patients, with Week 16 data expected in the first quarter of 2027.

Simultaneously, the ORCA-SPLASH Phase 2 trial is evaluating ORKA-002 in hidradenitis suppurativa (HS), a chronic and notoriously difficult-to-treat inflammatory skin condition that has recently become a major focus for pharmaceutical developers. By targeting both the IL-23 and IL-17 pathways across its portfolio, the company is hedging its clinical bets and expanding its total addressable market, ensuring it can capture patients who may not respond optimally to a single mechanism of action.

Furthermore, the pipeline is deepening with ORKA-004, a novel, subcutaneously administered, half-life extended monoclonal antibody targeting TL1A. TL1A has emerged as one of the most hotly contested targets in the autoimmune space, implicated in various inflammatory and fibrotic diseases. This asset remains on track for clinical initiation in the fourth quarter of 2026.

Crucially, the company plans to initiate Phase 2 combination studies of ORKA-004 alongside either ORKA-001 or ORKA-002 in 2027. This signals a sophisticated strategy to move beyond monotherapy, exploring synergistic effects that could set entirely new efficacy ceilings across a broad spectrum of severe inflammatory conditions.

To support this aggressive commercial and clinical expansion, the recent appointment of Todd Edwards as Chief Commercial Officer demonstrates that leadership is already laying the groundwork for market entry. Bringing 25 years of experience from companies like Arcutis Biotherapeutics, his addition suggests Oruka is not just focused on clearing regulatory hurdles, but is actively preparing to wage a commercial war against the established giants of dermatology.